101 episodes

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday.The host is Jim Cornall.

Beyond Biotech - the podcast from Labiotech Labiotech

    • News
    • 3.0 • 2 Ratings

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday.The host is Jim Cornall.

    Looking to cure Type 1 diabetes

    Looking to cure Type 1 diabetes

    Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 diabetes and LADA (latent autoimmune diabetes in adults). Diamyd is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production. It has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation. DIAGNODE-3, a confirmatory phase 3 trial, uses injections into a superficial lymph node can to optimize the treatment response.&...

    • 23 min
    Developing treatments for rare pediatric diseases

    Developing treatments for rare pediatric diseases

    Rare diseases affect around 1 in 2,000 people. Many of the thousands of rare diseases are difficult to diagnose. Of the known rare diseases, about 80% have genetic causes. Leukodystrophies are a group of rare genetic disorders for which there is currently no curative therapy.This week on the podcast we are discussing novel treatments of rare pediatric diseases in a conversation with Dan Williams, CEO, executive director and co-founder of Synaptix Bio. Synaptix Bio is working on developi...

    • 29 min
    Can cell therapy tackle hearing loss?

    Can cell therapy tackle hearing loss?

    Hearing loss is a huge – and growing – global challenge.Using its OSPREY platform, UK-based Rinri Therapeutics is developing a portfolio of off-the-shelf regenerative cell therapy products to address sensorineural hearing loss, a significant global medical challenge. The company’s lead asset, Rincell-1, is designed to regenerate auditory neurons and provide a novel treatment for patients with severe-to-profound age-related hearing loss or auditory neuropathy. The company is looking to st...

    • 31 min
    How biotech is tackling myasthenia gravis

    How biotech is tackling myasthenia gravis

    June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the skeletal muscles. It especially affects the voluntary muscles of the eyes, mouth, throat and/or limbs. It is most frequent in women from 20 and 30 and men aged 50 and older. To talk about the disease, how it is being treated, and what is in the pipeline for future treatments, we had a c...

    • 28 min
    Antisense oligonucleotides

    Antisense oligonucleotides

    German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications.The company’s lead compound, ISTH0036, is in clinical development in ophthalmology.On the podcast this week we chat with René Rückert, chief opera...

    • 27 min
    Making waves in cardiovascular disease treatment

    Making waves in cardiovascular disease treatment

    Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised.This week, we have a conversation with the CEO of Cytokinetics, Robert Blum, about the company’s aficamten, its next-in-class cardiac myosin inhibitor, prior to results from a phase 3 clinica...

    • 21 min

Customer Reviews

3.0 out of 5
2 Ratings

2 Ratings

Top Podcasts In News

Candace
Candace Owens
The Daily
The New York Times
The Tucker Carlson Show
Tucker Carlson Network
Up First
NPR
Pod Save America
Crooked Media
The Ben Shapiro Show
The Daily Wire

You Might Also Like

Business Of Biotech
Matt Pillar
The Long Run with Luke Timmerman
Timmerman Report
The Readout Loud
STAT
Raising Health
Andreessen Horowitz
Biotech 2050 Podcast
Biotech 2050
Biotech Hangout
Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more